Morgan Stanley analyst Terence Flynn lowered the firm’s price target on Regeneron (REGN) to $1,081 from $1,150 and keeps an Overweight rating on the shares. The firm adjusted its large cap pharma and biotech models for IQVIA trends as well as intra-quarter updates ahead of Q1 earnings reporting season for the group.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron Faces Financial Challenges Amid Co-Pay Assistance Funding Shortfall, Prompting Sell Rating
- Regeneron price target lowered to $925 from $950 at Oppenheimer
- Needham healthcare analysts hold analyst/industry conference call
- Gilead, Regeneron have most theoretical PDUFA date risk, says BofA
- Optimistic Long-Term Growth for Regeneron Amid Near-Term Challenges